Table 1.
Patient, Tumor, and Treatment characteristics
| Characteristic | All Patients (n,%) | Any Invasion |
|---|---|---|
| Total |
87 (100) |
25 (29) |
| Gender |
|
|
| Male |
68 (78) |
19 (76) |
| Female |
19 (22) |
6 (24) |
| Age |
Median = 57 years (range 33 – 81) |
Median = 58 years (range 41 – 81) |
| Ethnicity |
|
|
| Caucasian/Other |
49 (56) |
13 (52) |
| African-American |
38 (44) |
12 (48) |
| KPS score |
|
|
| 50 - 80 |
73 (84) |
21 (84) |
| 90 - 100 |
14 (16) |
4 (16) |
| Primary site with T-stage |
|
|
|
Larynx |
78 (90) |
21 (84) |
| T3 |
44 (51) |
2 (8) |
| T4a |
30 (34) |
18 (72) |
| T4b |
4 (5) |
1 (4) |
|
Hypopharynx |
9 (10) |
4 (16) |
| T4 |
8 (9) |
4(16) |
| T4b |
1 (1) |
0 (0) |
| N-stage |
|
|
| N0 |
34 (39) |
11 (44) |
| N1 |
11 (13) |
6 (24) |
| N2 |
35 (40) |
5 (20) |
| N3 |
7 (8) |
3 (12) |
| Overall Stage |
|
|
| III |
24 (28) |
1 (4) |
| IVA |
53 (61) |
20 (80) |
| IVB |
10 (11) |
4 (16) |
| Concurrent Therapy |
|
|
| None |
9 (10) |
2 (8) |
| Cetuximab |
6 (7) |
1 (4) |
| Cytotoxic Chemotherapy |
72 (83) |
22 (88) |
| Neoadjuvant Chemotherapy |
|
|
| No |
75 (86) |
21 (84) |
| Yes |
12 (14) * |
4 (16) |
| Fractionation of RT |
|
|
| Conventional |
39 (45) |
9 (36) |
| Altered Fractionation |
48 (55) |
16 (64) |
| IMRT |
|
|
| Yes |
52 (60) |
15 (60) |
| No |
35 (40) |
10 (40) |
| Local Recurrence |
|
|
| Yes |
17 (20) |
7 (28) |
| No |
70 (80) |
18 (72) |
| Regional Recurrence |
|
|
| Yes |
5 (6) |
1 (4) |
| Synchronous with LR |
3 (60) |
1(100) |
| Isolated |
2 (40) |
0 (0) |
| No |
82 (94) |
24 (96) |
| Distant Metastasis |
|
|
| Yes |
16 (18) |
4 (16) |
| No | 71 (82) | 21 (84) |
* 11 of 12 received concurrent chemoradiotherapy after induction and one received radiotherapy alone.